Latest Stock Buy or Sell?

Stockchase Research Editor: Michael O'Reilly This owner of 10,000 pharmacies across the US, who fills more than 20% of all prescriptions in the country, is reiterated again as a TOP PICK. The company announced a partnership with MSFT to bring more cloud based services to its customers, which should reduce costs and help retain customers. Forward earnings project the stock at 11x earnings, compared to peers at 15x and it trades under 2x book. It has been increasing cash reserves, while aggressively retiring debt. It pays a good dividend, backed by a payout ratio under 40% of cash flow. We would recommend adjusting the stop to $90.00, looking to achieve $117.50 - upside potential over 16%. Yield 2.18% (Analysts’ price target is $117.52)

Stockchase Research Editor: Michael O'Reilly ABT has benefited from COVID-19 testing worldwide, is the second largest cardiologic technology company in the world, and is a large player in the continuous glucose monitoring market for diabetes. It trades at 30x earnings, compared to peers at 23x; however, forward earnings support a 23x valuation. It is a little expensive at over 5x book value. It pays a small dividend (that has been growing for 50 years consecutively), backed by a payout ratio under 50% of cash flow. Its most recent earnings beat expectations by 11% and support a strong 27% ROE. It has been building cash reserves while paying down debt. We would recommend setting a stop loss at $105, looking to achieve $143 -- 18% upside potential. Yield 1.59% (Analysts’ price target is $142.88)

Stockchase Research Editor: Michael O'Reilly The cash flow being generated by the company is certainly strong enough to support outstanding debit and weather the risk of rising interest rates, placing it in an advantageous position relative to its competitors. It trades at 25x earnings compared to 35x for its peers. Latest earnings beat analyst estimates by 15% and supports a strong 31% ROE. It has been using some cash reserves to buyback substantial volumes of shares and pay down debt. We recommend placing a stop loss at $2200, looking to achieve $3465 -- upside potential over 22%. Yield 0% (Analysts’ price target is $3465.00)

(A Top Pick Mar 17/22, Down 10.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CFG has triggered its stop at $44. To remain disciplined, we recommend covering the position at this time. This results in a net investment loss of 6%, when combined with the previous buy recommendation.

(A Top Pick Mar 15/22, Up 35.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with TOU has achieved its $59.50 objective. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $42.50) to $47.50.

(A Top Pick Mar 29/22, Down 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NYCB has triggered its stop at $10.50. To remain disciplined, we recommend covering the position at this time. This results in a net investment loss of 9%, when combined with the previous buy recommendation.

(A Top Pick Jan 06/22, Up 84.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MOS is progressing well. We now recommend trailing up the stop (from $40) to $55.